Conjugates enhancing total cellular accumulation
Inventors
BEAUDOIN, Simon • LEYTON, Jeffrey Victor
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present description relates to a conjugated compound comprising cholic acid (ChAc) or a variant thereof, the ChAc conjugated to a non-cell penetrating peptide comprising a nuclear localization sequence (NLS) conjugated to a compound of interest.
Core Innovation
Cholic acid (ChAc) is conjugated to a nuclear localization sequence (NLS) containing peptide as set forth in SEQ ID NO: 1 to form a ChAcNLS construct. The ChAcNLS is further conjugated to an antibody covalently linked to the NLS/ChAc system to produce a conjugated compound with a cargo payload.
The described problem is endosome/lysosome entrapment, which limits delivery of cargo to the nucleus. The invention addresses this by using the ChAcNLS to enhance nuclear translocation and route cargo to the nucleus, including providing a nuclear reservoir for enhanced total intracellular accumulation.
Documented results include selective increases in nuclear translocation and total uptake in IL-3Rα+ TF-1a cells versus IL-3Rα− Raji cells, increased nuclear retention of 64Cu, improved intracellular accumulation, altered IL-3Rα trafficking toward recycling rather than degradation, and preservation of antibody affinity/selectivity. The concept is extended to radioconjugates (64Cu) and antibody-drug conjugates (ADCs), including T-DM1/emtansine and vinblastine-containing constructs, with claimed improvements in cytotoxicity and reduced off-target effects.
Claims Coverage
The partial claim set includes one independent claim directed to a covalently linked antibody–NLS (SEQ ID NO: 1)–cholic acid conjugated compound, with multiple dependent claims refining the antibody identity and payload class, and adding at least one quantitative conjugation-density constraint. The main inventive features are the specific covalent linkage architecture using SEQ ID NO: 1, the attachment to cholic acid, the antibody covalency, and dependent refinements defining antibody type and payload composition categories including radionuclides and named toxin molecules.
Antibody covalently linked to SEQ ID NO: 1 NLS
A conjugated compound consisting essentially of an antibody covalently linked to a nuclear localization sequence (NLS) as set forth in SEQ ID NO: 1.
NLS covalently linked to cholic acid (ChAc)
Said NLS covalently linked to cholic acid (ChAc), forming a cholic acid–NLS architecture within the conjugated compound.
Humanized antibody as the antibody
The conjugated compound where the antibody is a humanized antibody.
7G3 or 6G7 antibody as the antibody
The conjugated compound where the antibody is either the 7G3 antibody or the 6G7 antibody.
Conjugation density of ChAcNLS peptide per antibody
The conjugated compound defined such that the ratio of ChAcNLS peptide conjugated per antibody is between 1 to 21 peptides per compound.
Radionuclide payload in the composition
The composition characterized such that its payload is a radionuclide.
Named toxin payload options in the composition
The composition characterized by the toxin molecule being vinblastine, emtansine, Monomethyl auristatin E, or 4,4-difluoro-8-(4-carbwryphenyl)-1,3,5,7-tetramethyl-4-bora-3a,4a-diaza-s-indacene (BODIPY).
Across the provided independent claim and its dependents, coverage centers on a conjugated compound comprising an antibody covalently linked to an NLS as set forth in SEQ ID NO: 1, with that NLS covalently linked to cholic acid (ChAc). Further coverage includes refinements on the antibody identity (humanized; 7G3 or 6G7), a peptide-to-antibody conjugation ratio range (1 to 21 peptides per compound), and payload-related narrowing to radionuclides and named toxin molecules such as vinblastine and emtansine.
Stated Advantages
Increases nuclear translocation and total uptake selectively in IL-3Rα+ TF-1a cells versus IL-3Rα− Raji cells.
Increases nuclear retention of 64Cu and improves intracellular accumulation.
Alters IL-3Rα trafficking toward recycling rather than degradation.
Preserves antibody affinity/selectivity.
Provides claimed improvements in cytotoxicity and reduced off-target effects for ADC extensions.
Documented Applications
IL-3Rα-targeted intracellular delivery where ChAcNLS increases nuclear translocation and accumulation in IL-3Rα+ TF-1a cells versus IL-3Rα− Raji cells.
Radioconjugates using 64Cu with increased nuclear retention and improved intracellular accumulation.
Antibody-drug conjugates (ADCs), including T-DM1/emtansine and vinblastine-containing constructs, with claimed improvements in cytotoxicity and reduced off-target effects.
Interested in licensing this patent?